Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines

Inbal Hazan-Halevy, Dalit Landesman-Milo, Daniel Rosenblum, Shoshy Mizrahy, Brandon D. Ng, Dan Peer

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Hematological malignancies are a group of diseases characterized by clonal proliferation of blood-forming cells. Malignant blood cells are classified as myeloid or lymphoid cells depending on their stem cell origin. Lymphoid malignancies are characterized by lymphocyte accumulation in the blood stream, in the bone marrow, or in lymphatic nodes and organs. Several of these diseases are associated with chromosomal translocations, which cause gene fusion and amplification of expression, while others are characterized with aberrant expression of oncogenes. Overall, these genes play a major role in development and maintenance of malignant clones. The discovery of antisense oligonucleotides and RNA interference (RNAi) mechanisms offer new tools to specifically manipulate gene expression. Systemic delivery of inhibitory oligonucleotides molecules for manipulation of gene expression in lymphocytes holds a great potential for facilitating the development of an oligonucleotides -based therapy platform for lymphoid blood cancer. However, lymphocytes are among the most difficult targets for oligonucleotides delivery, as they are resistant to conventional transfection reagents and are dispersed throughout the body, making it difficult to successfully localize or deliver oligonucleotides payloads via systemic administration. In this review, we will survey the latest progress in the field of oligonucleotides based nanomedicine in the heterogeneous group of hematological malignancies with special emphasis on RNA based strategies. We will describe the most advanced non-viral nanocarriers for RNA delivery to malignant blood cells. We will also discuss targeted strategies for cell specific delivery of RNA molecules using nanoparticles and the therapeutic benefit of manipulating gene function in hematological malignancies. Finally, we will focus on the ex vivo, in vivo, and clinical trial strategies, that are currently under development in hematological malignancies - strategies that might increase the arsenal of drugs available to hematologists in the upcoming years.

Original languageEnglish (US)
Pages (from-to)149-156
Number of pages8
JournalJournal of Controlled Release
StatePublished - Dec 28 2016


  • Hematological malignancies
  • Nanoparticles
  • RNAi
  • Targeted delivery

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines'. Together they form a unique fingerprint.

Cite this